This site is intended for healthcare professionals
News

Approval of Trodelvy in China for second-line metastatic triple-negative breast cancer.- Everest Medicines + Immumomedics /Gilead

Read time: 1 mins
Published:19th Jun 2022

Everest Medicines a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that China's National Medical Products Administration (NMPA) has approved Trodelvy (sacituzumab govitecan or SG) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

 

This is the first drug that Everest has obtained New Drug Application (NDA) approval to launch in China. In May 2021, the NMPA accepted Everest's NDA for Trodelvy with Priority Review designation.

Condition: Breast Cancer Triple Neg
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights